Abstract
The ubiquitin-proteasome pathway (UPP), which influences essential cellular functions including cell growth, differentiation, apoptosis, signal transduction, antigen processing and inflammatory responses, has been considered as one of the most important cellular protein degradation approaches. Proteasome functions as a gatekeeper, which controls the execution of protein degradation and plays a critical role in the ubiquitin-proteasome pathway. The unfolding of the close connection between proteasome and cancer provides a potential strategy for cancer treatment by using proteasome inhibitors. Small molecular inhibitors of varied structures and potency against proteasome have been discovered in recent years, with bortezomib and carfilzomib having been successfully approved for clinical application while some other promising candidates are currently under clinical trials. Herein, we review the development history of drugs and candidates that target the 20S proteasome, structure-activity relationships (SARs) of various proteasome inhibitors, and related completed or ongoing clinical trials.
Keywords: Cancer, clinical development, marketed, proteasome, proteasome inhibitor, SAR.
Current Medicinal Chemistry
Title:Clinical and Marketed Proteasome Inhibitors for Cancer Treatment
Volume: 20 Issue: 20
Author(s): Jiankang Zhang, Peng Wu and Yongzhou Hu
Affiliation:
Keywords: Cancer, clinical development, marketed, proteasome, proteasome inhibitor, SAR.
Abstract: The ubiquitin-proteasome pathway (UPP), which influences essential cellular functions including cell growth, differentiation, apoptosis, signal transduction, antigen processing and inflammatory responses, has been considered as one of the most important cellular protein degradation approaches. Proteasome functions as a gatekeeper, which controls the execution of protein degradation and plays a critical role in the ubiquitin-proteasome pathway. The unfolding of the close connection between proteasome and cancer provides a potential strategy for cancer treatment by using proteasome inhibitors. Small molecular inhibitors of varied structures and potency against proteasome have been discovered in recent years, with bortezomib and carfilzomib having been successfully approved for clinical application while some other promising candidates are currently under clinical trials. Herein, we review the development history of drugs and candidates that target the 20S proteasome, structure-activity relationships (SARs) of various proteasome inhibitors, and related completed or ongoing clinical trials.
Export Options
About this article
Cite this article as:
Zhang Jiankang, Wu Peng and Hu Yongzhou, Clinical and Marketed Proteasome Inhibitors for Cancer Treatment, Current Medicinal Chemistry 2013; 20 (20) . https://dx.doi.org/10.2174/09298673113209990122
DOI https://dx.doi.org/10.2174/09298673113209990122 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Physiological and Pathophysiological Roles of ATP-Sensitive K+ Channels in Vascular Smooth Muscle
Vascular Disease Prevention (Discontinued) Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Surfactant Therapy of Pulmonary Conditions Excluding those with Primary Surfactant Deficiency and Bronchoscopy as Delivery Method: An Overview of Russian Patents and Publications
Recent Patents on Drug Delivery & Formulation COVID-19 and Renal Diseases: An Update
Current Drug Targets Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Recent Advances of Hepsin-Targeted Inhibitors
Current Medicinal Chemistry Cyclosporin A: A Therapeutic Strategy in Allergic Diseases
Letters in Drug Design & Discovery Sequence-Based Prediction of Protein-Protein Interactions by Means of Rotation Forest and Autocorrelation Descriptor
Protein & Peptide Letters Placebo Effect in Obsessive-Compulsive Disorder (OCD). Placebo Response and Placebo Responders in OCD: The Trend Over Time
Current Neuropharmacology Radiotherapy for Non-Melanoma Skin Cancer
Current Cancer Therapy Reviews Molecular Interactions of Zyesami with the SARS-CoV-2 nsp10/nsp16 Protein Complex
Combinatorial Chemistry & High Throughput Screening Discovery of the Factor Xa Inhibitor, ZK 807834 (CI-1031)
Current Topics in Medicinal Chemistry Antimycobacterial Agents: Synthesis and Biological Evaluation of Novel 4-(Substituted-phenyl)-6-methyl-2-oxo-N-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine- 5-carboxamide Derivatives by Using One-pot Multicomponent Method
Letters in Drug Design & Discovery Editorial [Hot Topic:Melanin-Concentrating Hormone (MCH) (Guest Editor: Andrew J. Souers)]
Current Topics in Medicinal Chemistry Evaluating the Risk of Covid-19 Transmission from Conjunctival and Lacrimal Discharge: A Review
Current Biotechnology Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics
Current Signal Transduction Therapy Molecular Elucidation and Therapeutic Targeting for Combating COVID-19: Current Scenario and Future Prospective
Current Molecular Medicine Malononitrile as a Key Reagent in Multicomponent Reactions for the Synthesis of Pharmaceutically Important Pyridines
Current Organic Chemistry Synthesis and Some Reactions of 1-aryl-4-acetyl-5-methyl-1,2,3-triazole Derivatives with Anticonvulsant Activity
Mini-Reviews in Medicinal Chemistry Malignant Pleural Effusion Evaluation and Management
Current Respiratory Medicine Reviews